NOVO NORDISK SEMAGLUTIDE APPROVED FOR LONG-TERM WEIGHT MANAGEMENT IN CHINA - COMPANY STATEMENT
Novo Nordisk Semaglutide Approved For Long-Term Weight Managemen…
![Reuters logo](/images/reuters.jpg)
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,006 DKK | +0.30% |
|
+1.79% | +44.05% |
Jun. 28 | India plans incentives for diabetes, obesity drug makers in 2026, government official says | RE |
Jun. 28 | NOVO NORDISK : UBS gives a Neutral rating | ZD |
NOVO NORDISK SEMAGLUTIDE APPROVED FOR LONG-TERM WEIGHT MANAGEMENT IN CHINA - COMPANY STATEMENT
1st Jan change | Capi. | |
---|---|---|
+44.05% | 638B | |
+55.32% | 819B | |
-6.75% | 351B | |
+13.56% | 329B | |
+10.68% | 298B | |
+16.57% | 242B | |
+2.04% | 225B | |
+13.31% | 217B | |
+8.48% | 168B | |
-2.81% | 158B |